What major adverse effect is associated with the use of Ticlopidine?

Ticlopidine is associated with a significant adverse effect known as aplastic anemia, which is a potentially life-threatening condition. Aplastic anemia occurs when the bone marrow fails to produce sufficient amounts of blood cells, leading to a deficiency of red blood cells, white blood cells, and platelets. This can result in severe complications, including increased risk of infections, uncontrolled bleeding, and fatigue.

The incidence of aplastic anemia in patients treated with Ticlopidine, although rare, is a critical concern that necessitates regular monitoring of blood counts during therapy. This side effect is particularly important because it highlights the need for careful consideration when prescribing Ticlopidine, especially in patients who may have pre-existing conditions that could increase the risk of hematological issues.

Other options listed do not have the same association with Ticlopidine. While gastrointestinal bleeding can occur with various antiplatelet medications, it is not the primary adverse effect linked specifically to Ticlopidine. Similarly, pneumonia and renal failure are not known to be major concerns associated with its use. Understanding the risk of aplastic anemia is crucial for safe and effective patient management when utilizing Ticlopidine as an antiplatelet therapy.